|
1
|
McBride WG: Thalidomide embryopathy.
Teratology. 16:79–82. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kim JH and Scialli AR: Thalidomide: The
tragedy of birth defects and the effective treatment of disease.
Toxicol Sci. 122:1–6. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Melchert M and List A: The thalidomide
saga. Int J Biochem Cell Biol. 39:1489–1499. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ito T, Ando H and Handa H: Teratogenic
effects of thalidomide: Molecular mechanisms. Cell Mol Life Sci.
68:1569–1579. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Singhal S, Mehta J, Desikan R, Ayers D,
Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar
M, et al: Antitumor activity of thalidomide in refractory multiple
myeloma. N Engl J Med. 341:1565–1571. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
de Souza CM, Silva Araújo e AC, de Jesus
Ferraciolli C, Moreira GV, Campos LC, dos Reis DC, Lopes MT,
Ferreira MA, Andrade SP and Cassali GD: Combination therapy with
carboplatin and thalidomide suppresses tumor growth and metastasis
in 4T1 murine breast cancer model. Biomed Pharmacother. 68:51–57.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee SM and Hackshaw A: A potential new
enriching trial design for selecting non-small-cell lung cancer
patients with no predictive biomarker for trials based on both
histology and early tumor response: Further analysis of a
thalidomide trial. Cancer Med. 2:360–366. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lv J, Liu N, Liu KW, Ding AP, Wang H and
Qiu WS: A randomised controlled phase II trial of the combination
of XELOX with thalidomide for the first-line treatment of
metastatic colorectal cancer. Cancer Biol Med. 9:111–114.
2012.PubMed/NCBI
|
|
9
|
Rezvani H, Haghighi S, Ghadyani M and
Attarian H: Efficacy of taxotere, thalidomide, and prednisolone in
patients with hormone-resistant metastatic prostate cancer. Urol J.
9:673–677. 2012.PubMed/NCBI
|
|
10
|
Tunio MA, Hashmi A, Qayyum A, Naimatullah
N and Masood R: Low-dose thalidomide in patients with metastatic
renal cell carcinoma. J Pak Med Assoc. 62:876–879. 2012.PubMed/NCBI
|
|
11
|
de Almeida MV, Teixeira FM, de Souza MV,
Amarante GW, Alves CC, Cardoso SH, Mattos AM, Ferreira AP and
Teixeira HC: Thalidomide analogs from diamines: Synthesis and
evaluation as inhibitors of TNF-alpha production. Chem Pharm Bull
(Tokyo). 55:223–226. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dmoszynska A, Podhorecka M, Manko J,
Bojarska-Junak A, Rolinski J and Skomra D: The influence of
thalidomide therapy on cytokine secretion, immunophenotype, BCL-2
expression and microvessel density in patients with resistant or
relapsed multiple myeloma. Neoplasma. 52:175–181. 2005.PubMed/NCBI
|
|
13
|
Marriott JB, Clarke IA, Czajka A, Dredge
K, Childs K, Man HW, Schafer P, Govinda S, Muller GW, Stirling DI
and Dalgleish AG: A novel subclass of thalidomide analogue with
anti-solid tumor activity in which caspase-dependent apoptosis is
associated with altered expression of bcl-2 family proteins. Cancer
Res. 63:593–599. 2003.PubMed/NCBI
|
|
14
|
Gutman M, Szold A, Ravid A, Lazauskas T,
Merimsky O and Klausner JM: Failure of thalidomide to inhibit tumor
growth and angiogenesis in vivo. Anticancer Res. 16:3673–3677.
1996.PubMed/NCBI
|
|
15
|
Fantozzi A, Gruber DC, Pisarsky L, Heck C,
Kunita A, Yilmaz M, Meyer-Schaller N, Cornille K, Hopfer U,
Bentires-Alj M and Christofori G: VEGF-mediated angiogenesis Links
EMT-induced cancer stemness to tumor Initiation. Cancer Res.
74:1566–1575. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Takahashi S: Vascular endothelial growth
factor (VEGF), VEGF receptors and their inhibitors for
antiangiogenic tumor therapy. Biol Pharm Bull. 34:1785–1788. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fiorelli A, Vicidomini G, Di Domenico M,
Napolitano F, Messina G, Morgillo F, Ciardiello F and Santini M:
Vascular endothelial growth factor in pleural fluid for
differential diagnosis of benign and malignant origin and its
clinical applications. Interact Cardiovasc Thorac Surg. 12:420–424.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shibuya M: Structure and dual function of
vascular endothelial growth factor receptor-1 (Flt-1). Int J
Biochem Cell Biol. 33:409–420. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shibuya M: Vascular endothelial growth
factor receptor-1 (VEGFR-1/Flt-1): A dual regulator for
angiogenesis. Angiogenesis. 9:225–231. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu H, Zhao C, Liu F, Wang L, Feng J, Zhou
Z, Qu L, Shou C and Yang Z: Radiolabeling and evaluation of
(64)Cu-DOTA-F56 peptide targeting vascular endothelial growth
factor receptor 1 in the molecular imaging of gastric cancer. Am J
Cancer Res. 5:3301–3310. 2015.PubMed/NCBI
|
|
21
|
Lesslie DP, Summy JM, Parikh NU, Fan F,
Trevino JG, Sawyer TK, Metcalf CA, Shakespeare WC, Hicklin DJ,
Ellis LM and Gallick GE: Vascular endothelial growth factor
receptor-1 mediates migration of human colorectal carcinoma cells
by activation of Src family kinases. Br J Cancer. 94:1710–1717.
2006.PubMed/NCBI
|
|
22
|
Ning Q, Liu C, Hou L, Meng M, Zhang X, Luo
M, Shao S, Zuo X and Zhao X: Vascular endothelial growth factor
receptor-1 activation promotes migration and invasion of breast
cancer cells through epithelial-mesenchymal transition. PLoS One.
8:e652172013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang ES, Teruya-Feldstein J, Wu Y, Zhu Z,
Hicklin DJ and Moore MA: Targeting autocrine and paracrine VEGF
receptor pathways inhibits human lymphoma xenografts in vivo.
Blood. 104:2893–2902. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kaplan RN, Riba RD, Zacharoulis S, Bramley
AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, et
al: VEGFR1-positive haematopoietic bone marrow progenitors initiate
the pre-metastatic niche. Nature. 438:820–827. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qian BZ, Zhang H, Li J, He T, Yeo EJ,
Soong DY, Carragher NO, Munro A, Chang A, Bresnick AR, et al: FLT1
signaling in metastasis-associated macrophages activates an
inflammatory signature that promotes breast cancer metastasis. J
Exp Med. 212:1433–1448. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kosaka Y, Mimori K, Fukagawa T, Ishikawa
K, Etoh T, Katai H, Sano T, Watanabe M, Sasako M and Mori M:
Identification of the high-risk group for metastasis of gastric
cancer cases by vascular endothelial growth factor receptor-1
overexpression in peripheral blood. Br J Cancer. 96:1723–1728.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou Z, Zhao C, Wang L, Cao X, Li J, Huang
R, Lao Q, Yu H, Li Y, Du H, et al: A VEGFR1 antagonistic peptide
inhibits tumor growth and metastasis through VEGFR1-PI3K-AKT
signaling pathway inhibition. Am J Cancer Res. 5:3149–3161.
2015.PubMed/NCBI
|
|
28
|
An P, Lei H, Zhang J, Song S, He L, Jin G,
Liu X, Wu J, Meng L, Liu M and Shou C: Suppression of tumor growth
and metastasis by a VEGFR-1 antagonizing peptide identified from a
phage display library. Int J Cancer. 111:165–173. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ye L, Yu G, Wang C, Du B, Sun D, Liu J, Qi
T, Yu X, Wei W, Cheng J and Jiang Y: MicroRNA-128a, BMI1 polycomb
ring finger oncogene and reactive oxygen species inhibit the growth
of U-87 MG glioblastoma cells following exposure to X-ray
radiation. Mol Med Rep. 12:6247–6254. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen H, Ye H, Meng DQ, Cai PC, Chen F, Zhu
LP, Tang Q, Long ZX, Zhou Q, Jin Y, et al: Reactive oxygen species
and X-Ray disrupted spontaneous [Ca2+]I oscillation in
alveolar macrophages. Radiat Res. 179:485–492. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gu ZT, Wang H, Li L, Liu YS, Deng XB, Huo
SF, Yuan FF, Liu ZF, Tong HS and Su L: Heat stress induces
apoptosis through transcription-independent p53-mediated
mitochondrial pathways in human umbilical vein endothelial cell.
Sci Rep. 4:44692014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Komorowski J, Jerczyńska H, Siejka A,
Barańska P, Ławnicka H, Pawłowska Z and Stepień H: Effect of
thalidomide affecting VEGF secretion, cell migration, adhesion and
capillary tube formation of human endothelial EA.hy 926 cells. Life
Sci. 78:2558–2563. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aydoğan S, Celiker U, Türkçüoğlu P, Ilhan
N and Akpolat N: The effect of thalidomide on vascular endothelial
growth factor and tumor necrosis factor-alpha levels in retinal
ischemia/reperfusion injury. Graefes Arch Clin Exp Ophthalmol.
246:363–368. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kozar K and Sicinski P: Cell cycle
progression without cyclin D-CDK4 and cyclin D-CDK6 complexes. Cell
Cycle. 4:388–391. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Baldin V, Lukas J, Marcote MJ, Pagano M
and Draetta G: Cyclin D1 Is a nuclear-protein required for cell
cycle progression in G1. Gene Dev. 7:812–821. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Robson S, Pelengaris S and Khan M: c-Myc
and downstream targets in the pathogenesis and treatment of cancer.
Recent Pat Anticancer Drug Discov. 1:305–326. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Qiao Z, Yuan J, Shen J, Wang C, He Z, Hu
Y, Zhang M and Xu C: Effect of thalidomide in combination with
gemcitabine on human pancreatic carcinoma SW-1990 cell lines in
vitro and in vivo. Oncol Lett. 9:2353–2360. 2015.PubMed/NCBI
|
|
38
|
Gill SS and Tuteja N: Reactive oxygen
species and antioxidant machinery in abiotic stress tolerance in
crop plants. Plant Physiol Biochem. 48:909–930. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chan CJ, Smyth MJ and Martinet L:
Molecular mechanisms of natural killer cell activation in response
to cellular stress. Cell Death Differ. 21:5–14. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fulda S, Gorman AM, Hori O and Samali A:
Cellular stress responses: Cell survival and cell death. Int J Cell
Biol. 2010:2140742010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu RY, Li X, Li L and Li GC: Expression
of human hsp70 in rat fibroblasts enhances cell survival and
facilitates recovery from translational and transcriptional
inhibition following heat shock. Cancer Res. 52:3667–3673.
1992.PubMed/NCBI
|
|
42
|
Noble EG, Melling CW and Milne KJ: HSP,
Exercise and Skeletal Muscle. Heat Shock Proteins Whole Body
Physiol. 5:285–316. 2010. View Article : Google Scholar
|
|
43
|
Nagashima M, Fujikawa C, Mawatari K, Mori
Y and Kato S: HSP70, the earliest-induced gene in the zebrafish
retina during optic nerve regeneration: Its role in cell survival.
Neurochem Int. 58:888–895. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Beere HM: ‘The stress of dying’: the role
of heat shock proteins in the regulation of apoptosis. J Cell Sci.
117:2641–2651. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kanagasabai R, Karthikeyan K, Vedam K,
Qien W, Zhu Q and Ilangovan G: Hsp27 protects adenocarcinoma cells
from UV-induced apoptosis by Akt and p21-dependent pathways of
survival. Mol Cancer Res. 8:1399–1412. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chu SH, Liu YW, Zhang L, Liu B and Li L,
Shi JZ and Li L: Regulation of survival and chemoresistance by
HSP90AA1 in ovarian cancer SKOV3 cells. Mol Biol Rep. 40:1–6. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wen W, Liu W, Shao Y and Chen L:
VER-155008, a small molecule inhibitor of HSP70 with potent
anti-cancer activity on lung cancer cell lines. Exp Biol Med
(Maywood). 239:638–645. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Azad AA, Zoubeidi A, Gleave ME and Chi KN:
Targeting heat shock proteins in metastatic castration-resistant
prostate cancer. Nat Rev Urol. 12:26–36. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Calderwood SK: Heat shock proteins in
breast cancer progression-a suitable case for treatment? Int J
Hyperthermia. 26:681–685. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Partida-Rodríguez O, Torres J, Flores-Luna
L, Camorlinga M, Nieves-Ramírez M, Lazcano E and Perez-Rodríguez M:
Polymorphisms in TNF and HSP-70 show a significant association with
gastric cancer and duodenal ulcer. Int J Cancer. 126:1861–1868.
2010.PubMed/NCBI
|
|
51
|
Calderwood SK, Khaleque MA, Sawyer DB and
Ciocca DR: Heat shock proteins in cancer: Chaperones of
tumorigenesis. Trends Biochem Sci. 31:164–172. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Staufer K and Stoeltzing O: Implication of
heat shock protein 90 (HSP90) in tumor angiogenesis: A molecular
target for anti-angiogenic therapy? Current Cancer Drug Targets.
10:890–897. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Dias S, Shmelkov SV, Lam G and Rafii S:
VEGF(165) promotes survival of leukemic cells by Hsp90-mediated
induction of Bcl-2 expression and apoptosis inhibition. Blood.
99:2532–2540. 2002. View Article : Google Scholar : PubMed/NCBI
|
